Skip to content

Evaluation of perioperative prophylaxis with levofloxacin in ureteroscopic stone removal: a prospective, multicenter, randomized, controlled trial

Evaluation of perioperative prophylaxis with levofloxacin in ureteroscopic stone removal: a prospective, multicenter, randomized, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019528
Enrollment
Unknown
Registered
2018-11-16
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral calculi

Interventions

Group 1:Levofloxacin tables
Group 2:Cephalosporin injection

Sponsors

Beijing Tongren Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with ureteral calculi who underwent retrograde semi-rigid ureteroscopic lithotripsy; or patients with renal calculi who underwent retrograde ureteroscopic lithotripsy (maximum diameter of stones <2 cm); 2) Aged 18-65 years old; 3) Sign the written informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with positive urine culture before surgery (the number of colonies in urine culture is =104/ml); 2) Patients with D-J tube = 2 weeks before surgery; 3) Patients with preoperative fever (body temperature = 38 degree C); 4) Patients with preoperative renal fistula; 5) Patients with moderate to severe hydronephrosis; 6) Patients with a history of diabetes; 7) Patients with low immunity or immunosuppressive agents; 8) Abnormal liver function (2 times normal upper limit of ALT and AST) and abnormal renal function (serum creatinine > 1.5 times normal upper limit); 9) Patients who are allergic to the test drug used; 10) Patients who have received antibiotic treatment within 72 hours prior to enrollment; 11) Patients with neuropathy or mental disorders who are unable to understand informed consent or cooperate with the study; 12) pregnant or lactating women; 13) Allergic to the study drug or contraindications; 14) The investigator considered it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
fever;

Secondary

MeasureTime frame
positive;RMB;

Countries

China

Contacts

Public ContactQiao Ludong

Beijing Tongren Hospital Affiliated to Capital Medical University

13910102618@163.com+86 13910102618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026